ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0136

Demographic and Clinical Characteristics of Patients with SLE Across 5 Registries – the LupusNet Federated Data Network

Federico Zazzetti1, Urbano Sbarigia2, William Giovanini3, Claire Blacketer4, Michel van Speybroeck5, Teresa A. Simon6, Guo Li3, Chetan S. Karyekar4, Reyhan Sonmez7, Manuel Ugarte-Gil8, RV, Gamboa-Cardenas9, Victor Pimentel-Quiroz10, Guillermo Pons-Estel11, Bernardo Pons-Estel12, Rosana Quintana13, Veronica Saurit14, ODIRLEI MONTICIELO15, Katiuzka Zuñiga Corrales16, Jorge Esquivel-Valerio17, Martin Rebella18, Cecilia Pisoni19, Francinne Machado Ribeiro20, Carlos Núñez-Álvarez21, Kaleb Michaud22, Patricia Katz23, Rangi Kandane-Rathnayake24, Eric Morand25, Worawit Louthrenoo26, Yi-Hsing Chen27, Jiacai Cho28, Laniyati Hamijoyo29, Shue Fen Luo30, Yeong-Jian Jan Wu30, Sandra Navarra31, Sargunan Sockalingam32, Masayoshi Harigai33, Zhuoli Zhang34, BMDB Basnayake35, Madelynn Chan36, Tsutomu Takeuchi37, Sang-Cheol Bae38, Fiona Goldblatt39, Sean O'Neill40, Kristine (Pek Ling) Ng41, Yih Jia Poh42, Nicola Tugnet43, Sunil Kumar44, Michael Tee45, Yoshiya Tanaka46 and Chak Sing. Lau47, Alberta Hoi48, Mandana Nikpour49, Mark Sapsford50, Íñigo Rúa-Figueroa50, José María Pego-Reigosa51, María Galindo-Izquierdo52, Jaime Calvo-Alén53, Antonio Fernández-Nebro54, Raúl Menor Almagro55 and Frederic Lavie56, 1Johnson & Johnson Innovative Medicine, Horsham, PA, PA, 2Johnson & Johnson Innovative Medicine, Brussels, Belgium, 3The Janssen Pharmaceutical Companies of Johnson & Johnson, Titusville, NJ, 4Janssen Research & Development, LLC, Spring House, PA, 5Janssen Pharmaceutica, Beerse, Belgium, 6Physicians Research Center, LLC, Toms River, NJ, 7EFOR-CVO Life Sciences Consultancy, Basel, Switzerland, 8Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas. Universidad Científica del Sur. Lima. Perú Servicio de Reumatología. Hospital Guillermo Almenara Irigoyen-EsSalud, Lima, Peru, 9Universidad Científica del Sur, Lima, Lima, Peru, 10Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru, 11Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina, 12Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, 13Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 14hospital privado universitario de cordoba, Córdoba, Argentina, 15HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, 16Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, 17Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, 18Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, 19CEMIC, Buenos Aires, Argentina, 20Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, 21Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico, Mexico, Mexico, 22University of Nebraska Medical Center, Omaha, NE, 23University of California San Francisco, San Francisco, CA, 24Monash University, Clayton, Victoria, Australia, 25School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, 26Chiang Mai University, Chang Wat Chiang Mai, Thailand, 27Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), 28National University Hospital, Kent Ridge, Singapore, 29University of Padjadjaran, Sumedang Regency and Bandung, Indonesia, 30Chang Gung Memorial Hospital, Taoyuan City, Taiwan (Republic of China), 31University of Santo Tomas, Manila, Philippines, 32University of Malaya Medical Centre, Kuala Lumpur, Malaysia, 33Tokyo Women's Medical University, Tokyo, Japan, 34Peking University First Hospital, Beijing, China, 35Teaching Hospital, Kandy, Sri Lanka, 36Tan Tock Seng Hospital, Singapore, Singapore, 37Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, 38Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 39Flinders Medical Centre, Adelaide, Australia, 40Liverpool Hospital; Royal North Shore Hospital; University of New South Wales and the University of Sydney, Sydney, New South Wales, Australia, 41Health New Zealand Waitemata, Te Whatu Ora (North Shore Hospital), Auckland, New Zealand, 42SingHealth, Singapore, Singapore, 43Auckland District Health Board, Auckland, New Zealand, 44Health New Zealand Counties Manukau, Te Whatu Ora (Middlemore Hospital), Auckland, New Zealand, 45University of the Philippines, Manila, Philippines, 46Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 47University of Hong Kong, Pok Fu Lam, Hong Kong, 48Monash Health, Monash University, Melbourne, AU, Melbourne, Victoria, Australia, 49The University of Sydney, Melbourne, Victoria, Australia, 50Middlemore Hospital, Auckland, New Zealand, 50Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, 6Galicia Health Service (SERGAS), Vigo, Spain, 52Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 53Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, 54Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain, 55Department of Rheumatology, Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, 56Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France

Meeting: ACR Convergence 2024

Keywords: Nephritis, Outcome measures, registry, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 16, 2024

Title: Epidemiology & Public Health Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with a broad range of clinical manifestations and a high unmet need across patient populations. Real-world data on SLE are scattered across many registries worldwide with heterogeneous data collection. The Lupus Federated Data Network (LupusNet) is an interdisciplinary international initiative that aims to combine and harmonize data from existing SLE registries to create a global, federated network of SLE databases with a larger number of patients, greater data consistency, and the potential to address gaps in understanding of SLE.

Methods: Data from 5 registries representing >10,000 patients with SLE from 4 regions contributed to LupusNet: APLC (Asia Pacific), RELESSER (Europe), FORWARD (North America), and Almenara and GLADEL (Central and South America). LupusNet uses a federated data network approach and a privacy-by-design method, where the data remains with the respective registries and analysis occurs at the local center, while only aggregated results are shared. Figure 1 illustrates the schedule of visits patients in each registry completed for clinical assessments, including SLEDAI. Demographic and clinical variables (eg, disease activity/severity, clinical events, biopsies/histology, biomarkers, treatment history, comorbidities, medications, and patient-reported outcomes) were mapped and harmonized to the Observational Medical Outcomes Partnership Common Data Model v5.4. This study describes the baseline demographics, characteristics, and disease activity based on the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) in LupusNet during ±90 days of registration.

Results: A total of 10,267 patients were included and mapped in LupusNet; of those, 3,908 patients were in Asia Pacific, 1,806 in Europe, 3,066 in North America, and 1,487 in Central and South America. Select baseline demographics and characteristics of patients with SLE are presented (Table 1). Disease activity based on the SLEDAI questionnaire assessed at registration is presented from 4 registries that collected these data (Table 2). Across registries, the majority of patients were female; the duration from SLE diagnosis to registry entry ranged from 5 to 10 years. Heterogeneity and variability in disease manifestations determined from SLEDAI responses were observed across registries, particularly in relation to arthritis, nephritis (ie, proteinuria, pyuria, hematuria, and urinary casts), increased anti-dsDNA antibody, and leukopenia.

Conclusion: Mapping patient characteristics from LupusNet allows researchers to analyze a larger population of patients with SLE across different geographical regions. These findings demonstrate a high degree of variability in disease activity measured by SLEDAI across registries, likely due to their differences in recruitment strategy, treatment strategy/access, healthcare system, and race/ethnicity. Compared to individual registries, this network of collective SLE databases allows further study to better understand disease heterogeneity, patient populations, and treatment patterns with the goal of improving outcomes for patients with SLE across the globe.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: F. Zazzetti: Janssen, 3, Johnson & Johnson, 11; U. Sbarigia: Janssen, 3, Johnson & Johnson, 11; W. Giovanini: Janssen, 3, Johnson & Johnson, 11; C. Blacketer: Janssen, 3, Johnson & Johnson, 11; M. van Speybroeck: Janssen, 3, Johnson & Johnson, 11; T. Simon: Janssen, 3, Johnson & Johnson, 11; G. Li: Janssen, 3, Johnson & Johnson, 11; C. Karyekar: Janssen, 3, Johnson & Johnson, 11; R. Sonmez: Janssen, 3, Johnson & Johnson, 11; M. Ugarte-Gil: AstraZeneca, 1, 5, 6, Ferrer, 1, GlaxoSmithKlein(GSK), 5, 6, Janssen, 1; R. Gamboa-Cardenas: None; V. Pimentel-Quiroz: None; G. Pons-Estel: Abbvie, 6, AstraZeneca, 1, 6, 12, Support to attend a scientific event, Boehringer-Ingelheim, 1, 2, 6, 12, Support to attend a scientific event, GSK, 1, 5, 6, Janssen, 1, 5, 6, Novartis, 1, 6, 12, Support to attend a scientific event, Pfizer, 1, 6, Remegen, 1, RemeGen, 1, 2, Remegen, 2, RemeGen, 5, 6, Remegen, 6, Sanofi, 1, 2, 5, 6, Werfen Diagnostics, 1, 2, 5, 6; B. Pons-Estel: AstraZeneca, 1, 6, GSK, 1, 6, Janssen, 1, 6; R. Quintana: None; V. Saurit: None; O. MONTICIELO: AbbVie/Abbott, 6, AstraZeneca, 6, GlaxoSmithKlein(GSK), 6, Janssen, 6, UCB, 6; K. Corrales: None; J. Esquivel-Valerio: None; M. Rebella: None; C. Pisoni: None; F. Ribeiro: None; C. Núñez-Álvarez: None; K. Michaud: None; P. Katz: None; R. Kandane-Rathnayake: GlaxoSmithKline(GSK), 5, Janssen, 5, Novartis, 5; E. Morand: AbbVie, 5, Amgen, 5, AstraZeneca, 1, 2, 5, 6, Biogen, 2, 5, Bristol Myers Squibb, 2, 5, Dragonfly, 2, Eli Lilly, 5, EMD Serono, 2, 5, Genentech, 2, 5, Gilead, 2, GSK, 2, 5, Janssen, 5, Novartis, 2, 5, RemeGen, 2, Roche, 5, 6, Takeda, 2, 5, UCB, 5, Zenas, 2; W. Louthrenoo: None; Y. Chen: None; J. Cho: None; L. Hamijoyo: None; S. Luo: None; Y. Wu: None; S. Navarra: Astellas, 6, AstraZeneca, 6, Biogen, 2, Boehringer-Ingelheim, 2, GlaxoSmithKlein(GSK), 6, Novartis, 6, Pfizer, 6; S. Sockalingam: None; M. Harigai: AbbVie/Abbott, 2, 5, 6, Boehringer-Ingelheim, 2, 5, 6, Bristol-Myers Squibb(BMS), 2, 6, Eli Lilly, 5, 6, Pfizer, 5, 6, UCB, 5; Z. Zhang: None; B. Basnayake: None; M. Chan: None; T. Takeuchi: AbbVie, 4, 6, Astellas, 2, 6, Eisai, 4, 6, Eli Lilly Japan, 2, 6, Gilead, 2, 6, Pfizer Japan, 6; S. Bae: None; F. Goldblatt: None; S. O'Neill: None; K. Ng: Novartis, 6; Y. Poh: None; N. Tugnet: None; S. Kumar: None; M. Tee: None; Y. Tanaka: AbbVie, 6, Asahi-kasei, 6, Astellas, 6, AstraZeneca, 6, Boehringer Ingelheim, 5, 6, Chugai, 5, 6, Daiichi Sankyo, 6, Eisai, 6, Gilead, 6, GSK, 6, Lilly, 6, Pfizer, 6, Taisho, 5, 6, UCB, 6; C. Lau: None; A. Hoi: AbbVie/Abbott, 6, AstraZeneca, 5, Australian Rheumatology- Association, 4, 12, Treasurer, Eli Lilly, 6, EUSA Pharma, 2, Limbic, 6, Moose Republic, 6, Novartis, 6; M. Nikpour: AstraZeneca, 2, 5, 6, Boehringer-Ingelheim, 2, 5, 6, Bristol-Myers Squibb(BMS), 5, GlaxoSmithKlein(GSK), 6, Janssen, 2, 5, 6; M. Sapsford: Novartis, 6; Í. Rúa-Figueroa: AstraZeneca, 2, 6, GlaxoSmithKlein(GSK), 2, 6, Otsuka, 2, 6; J. Pego-Reigosa: AstraZeneca, 1, 6, GSK, 5, 6, Otsuka, 1, Pfizer, 5, Roche, 1; M. Galindo-Izquierdo: None; J. Calvo-Alén: None; A. Fernández-Nebro: Argenx, 5, AstraZeneca, 2, 5, Chemo, 5, Eli Lilly, 2, Galapagos, 2, 5, Gebro Pharma, 2, GlaxoSmithKlein (GSK), 6, GSK, 2, Janssen, 5, Merck Serono, 5, MSD, 5, Novartis, 2, 5, Takeda, 5, UCB, 5; R. Menor Almagro: None; F. Lavie: Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, 3, Johnson & Johnson, 11.

To cite this abstract in AMA style:

Zazzetti F, Sbarigia U, Giovanini W, Blacketer C, van Speybroeck M, Simon T, Li G, Karyekar C, Sonmez R, Ugarte-Gil M, Gamboa-Cardenas R, Pimentel-Quiroz V, Pons-Estel G, Pons-Estel B, Quintana R, Saurit V, MONTICIELO O, Corrales K, Esquivel-Valerio J, Rebella M, Pisoni C, Ribeiro F, Núñez-Álvarez C, Michaud K, Katz P, Kandane-Rathnayake R, Morand E, Louthrenoo W, Chen Y, Cho J, Hamijoyo L, Luo S, Wu Y, Navarra S, Sockalingam S, Harigai M, Zhang Z, Basnayake B, Chan M, Takeuchi T, Bae S, Goldblatt F, O'Neill S, Ng K, Poh Y, Tugnet N, Kumar S, Tee M, Tanaka Y, Lau C, Hoi A, Nikpour M, Sapsford M, Rúa-Figueroa Í, Pego-Reigosa J, Galindo-Izquierdo M, Calvo-Alén J, Fernández-Nebro A, Menor Almagro R, Lavie F. Demographic and Clinical Characteristics of Patients with SLE Across 5 Registries – the LupusNet Federated Data Network [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/demographic-and-clinical-characteristics-of-patients-with-sle-across-5-registries-the-lupusnet-federated-data-network/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/demographic-and-clinical-characteristics-of-patients-with-sle-across-5-registries-the-lupusnet-federated-data-network/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology